Sarepta Therapeutics (0L35) Share Forecast & Price Target
0L35 Analyst Ratings
Hold
3Buy10Hold4Sell
Based on 17 analysts giving stock ratings to Sarepta Therapeutics in the past 3 months
0L35 Stock 12 Month Forecast
Average Price Target
$21.53▲(16.97% Upside)Based on 17 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $21.53 with a high forecast of $38.00 and a low forecast of $5.00. The average price target represents a 16.97% change from the last price of $18.41.
Past 12 Months12 Month ForecastDec2025Sep2026
High$38.00
Average$21.53
Low$5.00
Highest Price TargetHighest$38.00Average Price Target$21.53Lowest Price TargetLowest$5.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Mitchell Kapoor | H.C. Wainwright | $5 | sell | -72.84%Downside | Reiterated | 10/30/26 | ||
| Brian Abrahams | RBC Capital | $17 | hold | -7.66%Downside | Reiterated | 10/27/26 | ||
| Yun Zhong | Wedbush | $35 | buy | 90.11%Upside | Reiterated | 10/26/26 | ||
| Ritu Baral | TD Cowen | $17 | hold | -7.66%Downside | Reiterated | 10/21/26 | ||
| Biren Amin | Piper Sandler | $20 | hold | 8.64%Upside | Reiterated | 10/19/26 | ||
 Unknown AnalystNot Ranked | Leerink Partners | $20 | hold | 8.64%Upside | Reiterated | 10/15/26 | ||
| Tazeen Ahmad | Bank of America Securities | $18 | sell | -2.23%Downside | Reiterated | 10/09/26 | ||
| Yanan Zhu | Wells Fargo | $38 | buy | 106.41%Upside | Reiterated | 10/02/26 | ||
| Anupam Rama | J.P. Morgan | $23→$20 | hold | 8.64%Upside | Assigned | 09/30/26 | ||
| Gil Blum | Needham | ― | sell | ― | Reiterated | 09/28/26 | ||
| Lachlan Hanbury Brown | William Blair | ― | hold | ― | Reiterated | 09/28/26 | ||
| Yigal Nochomovitz | Citi | $13 | sell | -29.39%Downside | Reiterated | 09/27/26 | ||
| Gavin Clark-Gartner | Evercore ISI | $19 | hold | 3.20%Upside | Reiterated | 08/10/26 | ||
| Eliana Merle | Barclays | $20 | hold | 8.64%Upside | Reiterated | 08/07/26 | ||
| Michael Ulz | Morgan Stanley | $25 | hold | 35.80%Upside | Assigned | 08/06/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Mitchell Kapoor | 10/30/26 | $5 | sell | -72.84%Downside | Reiterated | H.C. Wainwright | ||
| Brian Abrahams | 10/27/26 | $17 | hold | -7.66%Downside | Reiterated | RBC Capital | ||
| Yun Zhong | 10/26/26 | $35 | buy | 90.11%Upside | Reiterated | Wedbush | ||
| Ritu Baral | 10/21/26 | $17 | hold | -7.66%Downside | Reiterated | TD Cowen | ||
| Biren Amin | 10/19/26 | $20 | hold | 8.64%Upside | Reiterated | Piper Sandler | ||
| Unknown AnalystNot Ranked | 10/15/26 | $20 | hold | 8.64%Upside | Reiterated | Leerink Partners | ||
| Tazeen Ahmad | 10/09/26 | $18 | sell | -2.23%Downside | Reiterated | Bank of America Securities | ||
| Yanan Zhu | 10/02/26 | $38 | buy | 106.41%Upside | Reiterated | Wells Fargo | ||
| Anupam Rama | 09/30/26 | $23→$20 | hold | 8.64%Upside | Assigned | J.P. Morgan | ||
| Gil Blum | 09/28/26 | ― | sell | ― | Reiterated | Needham | ||
| Lachlan Hanbury Brown | 09/28/26 | ― | hold | ― | Reiterated | William Blair | ||
| Yigal Nochomovitz | 09/27/26 | $13 | sell | -29.39%Downside | Reiterated | Citi | ||
| Gavin Clark-Gartner | 08/10/26 | $19 | hold | 3.20%Upside | Reiterated | Evercore ISI | ||
| Eliana Merle | 08/07/26 | $20 | hold | 8.64%Upside | Reiterated | Barclays | ||
| Michael Ulz | 08/06/26 | $25 | hold | 35.80%Upside | Assigned | Morgan Stanley |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Sarepta Therapeutics
3 Months
Success Rate14/18 ratings generated profit
78%
Average Return
+10.17%
Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +10.17% per trade.
1 Year
Success Rate13/18 ratings generated profit
72%
Average Return
+16.24%
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +16.24% per trade.
2 Years
Success Rate12/18 ratings generated profit
67%
Average Return
+13.81%
Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +13.81% per trade.
0L35 Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 5 | 6 | 8 |
| Buy | 1 | 2 | 1 | 1 | 0 |
| Hold | 12 | 13 | 13 | 15 | 17 |
| Sell | 2 | 4 | 4 | 6 | 5 |
| Strong Sell | 2 | 3 | 3 | 4 | 5 |
| total | 25 | 28 | 26 | 32 | 35 |
In the current month, 0L35 has received 8 Buy Ratings, 17 Hold Ratings, and 10 Sell Ratings. 0L35 average Analyst price target in the past 3 months is 21.53.
0L35 Financial Forecast
High$0.78
Consensus$0.07
Low$-0.50
0L35 Earnings Forecast
Next quarter’s earnings estimate for 0L35 is $0.07 with a range of -$0.50 to $0.78. The previous quarter’s EPS was -$0.05. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$382M
Consensus$352M
Low$322M
0L35 Sales Forecast
Next quarter’s sales forecast for 0L35 is $352.20M with a range of $322.44M to $381.50M. The previous quarter’s sales results were $401.25M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0L35 Stock Forecast FAQ
What is GB:0L35’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is $21.53.
What is GB:0L35’s upside potential, based on the analysts’ average price target?
Sarepta Therapeutics has 16.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Sarepta Therapeutics a Buy, Sell or Hold?
Sarepta Therapeutics has a consensus rating of Hold, which is based on 3 buy ratings, 10 hold ratings and 4 sell ratings.
What is Sarepta Therapeutics’s share price target?
The average share price target for Sarepta Therapeutics is $21.53. This is based on 17 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $38.00, and the lowest forecast is $5.00. The average share price target represents a 16.97% increase from the current price of $18.41.
What do analysts say about Sarepta Therapeutics?
Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 17 Wall Street analysts.
How can I buy shares of Sarepta Therapeutics?
To buy shares of GB:0L35, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.